AR and small cell carcinoma: However, after a period of treatment, castration resistance ultimately ensues and the disease may develop into androgen receptor (AR)-castration-resistant prostate cancer (CRPC) or even neuroendocrine prostate cancer (NEPC), an AR-negative small cell neuroendocrine carcinoma (5, 6).